GlassScriptPhysician profile
David J Pinhas
NPI 1386677706
$6,607.27
in general payments reported to CMS, 2019-2025
29 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $562 · 2021: $518 · 2022: $660 · 2023: $644 · 2024: $1,562 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,884.14 | 2020-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $658.87 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Miebo |
| Abbvie INC. | $543.05 | 2023-2025 | |
| Allergan, INC. | $441.44 | 2019-2021 | |
| Harrow Eye, LLC | $282.81 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $264.59 | 2019-2024 | Omni Surgical System |
| Dompe US, INC. | $230.90 | 2022-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $218.60 | 2021-2025 | Acthar |
| Thea Pharma INC. | $194.23 | 2023-2025 | Iyuzeh |
| New World Medical,INC. | $186.20 | 2022 | |
| Eyevance Pharmaceuticals LLC | $182.88 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $180.63 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $170.21 | 2024-2025 | Xdemvy |
| Akorn Operating Company LLC | $157.31 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $150.05 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $149.19 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $144.45 | 2019-2025 | |
| Oyster Point Pharma, INC. | $96.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ivantis, INC | $81.98 | 2020-2021 | |
| Astellas Pharma US INC | $81.06 | 2024-2025 | Izervay |
| Kala Pharmaceuticals, INC. | $76.38 | 2019-2021 | |
| Akorn, INC. | $61.53 | 2020 | |
| Rayner Intraocular Lenses Limited | $34.53 | 2022 | |
| Iridex Corporation | $26.14 | 2019 | |
| Amgen INC. | $25.28 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $24.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.24 | 2025 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $19.88 | 2022 | |
| Horizon Therapeutics Plc | $19.42 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pinhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.